We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Commercializing Protein Tomography Solutions

By Labmedica staff writers
Posted on 20 Mar 2006
Sidec Technologies (Torshmnagatan) and FEI company (Hillsboro) have announced that the two companies will collaborate on the commercialization of protein tomography solutions and software, using Sidec's software and intellectual property and FEI's transmission electron microscopes (TEMs). Based on current practices, protein tomography is estimated to be a U.S.$200 million market with the potential to grow several-fold within a few years.

Protein tomography was developed for studying the molecular nature of disease pathways and for validating preclinical models and investigating the activity of candidate therapeutics. Protein tomography makes it possible to visualize biomolecules in situ, even in a cell membrane. FEI has developed cryo-electron microscopy for the imaging of biologic structures in collaboration with academic groups in Europe and the United States. Sidec is developing protein imaging using cryo-electron microscopy, and has research collaborations with global pharmaceutical companies.

Advanced electron microscopy instrumentation, data acquisition, and reconstruction software that enable the imaging and analysis of individual protein molecules in cells and tissues are being offered by FEI and Sidec. The service is being provided through Sidec, as an on-premises service or through software and other intellectual property license arrangements, combined with a TEM sale.


Related Links:
Sidec
FEI

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Nuclear Matrix Protein 22 Test
NMP22 Test
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab

Latest Industry News

Bio-Techne and ALZpath Partner to Advance Neurodegenerative Disease Research and Treatment

Microbiologics Acquires Diagnostic Quality Controls Manufacturer SensID

Beckman Coulter Partners with BioPorto for Global Distribution of Acute Kidney Injury NGAL Tests